PROQR THERAPEUTICS EO-04 (0PQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PROQR THERAPEUTICS EO-04 (0PQ) has a cash flow conversion efficiency ratio of -0.271x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-13.36 Million ≈ $-15.62 Million USD) by net assets (€49.37 Million ≈ $57.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PROQR THERAPEUTICS EO-04 stock valuation for the company's overall valuation and market capitalisation.
PROQR THERAPEUTICS EO-04 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how PROQR THERAPEUTICS EO-04's cash flow conversion efficiency has evolved over time, based on yearly financial data.
PROQR THERAPEUTICS EO-04 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PROQR THERAPEUTICS EO-04 ranked by their cash flow conversion efficiency. See 0PQ operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Golden Long Teng Development Co Ltd
TWO:3188
|
0.098x |
|
Hooker Furniture Corporation
NASDAQ:HOFT
|
0.085x |
|
Hamat Group Ltd
TA:HAMAT
|
0.059x |
|
Oncolytics Biotech Inc
TO:ONC
|
-0.899x |
|
Votum SA
WAR:VOT
|
0.077x |
|
Oriental Precision & Engineering Co.Ltd
KQ:014940
|
0.088x |
|
Gabelli Healthcare & WellnessRx Trust
NYSE:GRX
|
0.079x |
|
Terra Metals Ltd
AU:TM1
|
-0.001x |
Annual Cash Flow Conversion Efficiency for PROQR THERAPEUTICS EO-04 (2021–2025)
The table below shows the annual cash flow conversion efficiency of PROQR THERAPEUTICS EO-04 from 2021 to 2025. View 0PQ share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €49.37 Million ≈ $57.72 Million |
€-52.79 Million ≈ $-61.72 Million |
-1.069x | -160.18% |
| 2024-12-31 | €88.56 Million ≈ $103.54 Million |
€-36.39 Million ≈ $-42.55 Million |
-0.411x | -178.93% |
| 2023-12-31 | €41.39 Million ≈ $48.39 Million |
€21.55 Million ≈ $25.19 Million |
0.521x | +150.67% |
| 2022-12-31 | €66.68 Million ≈ $77.96 Million |
€-68.51 Million ≈ $-80.09 Million |
-1.027x | -347.22% |
| 2021-12-31 | €113.23 Million ≈ $132.38 Million |
€-26.01 Million ≈ $-30.41 Million |
-0.230x | -- |
About PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more